Advertisements

Эквакард

Quick links to important sections

Эквакард

Advertisements
Advertisements

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Эквакард

Property Description
Active ingredient Amlodipine, Lisinopril
Form Oral Tablets
Pharmacological class Antihypertensive Agent
Type Fixed-Dose Combination (FDC)
Origin Synthetic

Эквакард (Ekvakard) is a dual-acting antihypertensive agent formulated as a Fixed-Dose Combination (FDC) preparation for oral administration. Its primary purpose is to help maintain stable control over arterial hypertension, commonly referred to as high blood pressure.


What Type of Medicine is Эквакард? (Definition and Classification)

Эквакард is classified as an Antihypertensive Agent, utilizing two distinct active compounds in one tablet to address elevated blood pressure via complementary pharmacological pathways. This combination is generally reserved for adult patients whose blood pressure is not adequately controlled by a single medication. The preparation is a synthetic medicine. The combination of a calcium channel blocker and an ACE inhibitor is recognized for treating high blood pressure and is used as a strategy in cardiovascular therapy.


Composition and Origin: The Combination of Amlodipine and Lisinopril

The formulation contains two pharmacologically distinct active ingredients: Amlodipine and Lisinopril (INN). Amlodipine belongs to the Calcium Channel Blocker (CCB) class, and Lisinopril is an Angiotensin-Converting Enzyme (ACE) inhibitor. This dual-class approach is associated with sustained efficacy compared to initial monotherapy. The use of FDC formulations like this is intended to support a patient's adherence to their prescribed long-term treatment plan. Combining the two medications into one tablet simplifies the daily routine for adult patients requiring complex regimens.


The General Benefit of a Dual-Acting Formulation

The core benefit of this FDC lies in its ability to achieve blood pressure reduction through two simultaneous physiological actions: Amlodipine promotes peripheral vasodilation (widening of the blood vessels), while Lisinopril acts to suppress the Renin-Angiotensin-Aldosterone System (RAAS). This comprehensive approach is characterized by achieving control over blood pressure, lowering the overall resistance to blood flow, and thereby lessening the chronic mechanical strain on the heart and arteries associated with uncontrolled hypertension.

Regulatory References

  1. Lisinopril: MedlinePlus Drug Information
Advertisements

What side effects are possible with Эквакард?

Possible Side Effects and Safety Information

The official safety profile for the fixed-dose combination of Amlodipine and Lisinopril is defined by the established regulatory data for its two active components, an ACE inhibitor and a calcium channel blocker. Adverse effects are formally categorized by frequency and the physiological system affected, following standards set by government health authorities.

Commonly documented adverse reactions (typically 1% - 10% incidence) include headache, dizziness, fatigue, nausea, and abdominal pain. Edema (swelling), particularly of the ankles, is frequently associated with the Amlodipine component, often in a dose-related manner. A persistent, dry cough is a well-known effect related to the Lisinopril component.

Serious Adverse Reactions are explicitly noted in regulatory documents. These include Angioedema (rapid swelling of the face, throat, or tongue), a potentially fatal reaction linked to ACE inhibitors. Symptomatic Hypotension (severe drop in blood pressure) is also a significant concern, particularly when therapy is initiated. Worsening Angina or Acute Myocardial Infarction can occur, particularly upon starting or increasing the Amlodipine dose in certain patients.

Population-Specific Safety Considerations are strictly defined. Use during the second and third trimesters of pregnancy is associated with fetal injury and death due to the Lisinopril component, constituting a major safety restriction. Caution is also noted for patients with severe hepatic impairment due to potential decreased clearance of Amlodipine.

These official classifications ensure a neutral, descriptive outline of the drug’s potential risks, separate from all dosing or therapeutic information.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information

Overdose scope

Property Description
Documented overdose presentations Marked and Prolonged Systemic Hypotension, Profound Hypotension, Excessive Peripheral Vasodilation, Reflex Tachycardia.
Physiological systems affected Cardiovascular system (hypotension, shock), Renal system (acute renal failure).
Dose-related or exposure-related factors Excessive dose or exposure leading to an exaggeration of the active ingredients' primary pharmacological effects.
Population-specific overdose notes Dialysis is unlikely to be of benefit. Increased risk of Hyperkalemia is noted, particularly with pre-existing renal impairment.
Emergency-response statements Symptomatic and Supportive Treatment is mandated; use of Intravenous Calcium Gluconate may be useful.
When immediate medical help is required Seek immediate medical attention; Close medicinal supervision, preferably in hospital, is required.

Overdose classifications (high-level)

Property Description
Severity classification Profound/Systemic Hypotension, Circulatory Shock, Acute Renal Failure, Potential for Death.
Regulatory basis Based on official Prescribing Information / Summary of Product Characteristics (SmPC) from government regulatory authorities.
Overdose-context constraints No specific antidote is known.

Resulting overdose structure

Official overdose statements:

  • The principal clinical manifestation is profound and prolonged systemic hypotension, which may progress to circulatory shock.
  • Immediate medical attention and prolonged observation are mandated due to the risk of severe cardiovascular consequences.
  • Management is strictly symptomatic and supportive, including volume expansion with intravenous fluids and the potential administration of Vasopressor Agents or Intravenous Calcium Gluconate.
  • Monitoring of Cardiac and Respiratory Function, Blood Pressure, and Serum Electrolytes is required.

Connection to the overall overdose profile: The regulatory documents define the overdose profile by focusing on the risk of severe cardiovascular instability, predominantly hypotension and shock, which necessitates seeking immediate medical attention. The official response is strictly procedural, mandating a range of supportive and symptomatic treatments—such as gastric decontamination, volume repletion, and specialized monitoring—because no specific antidote is known for the combination.

Advertisements

Therapeutic Uses of Эквакард

What Эквакард Treats: Main Uses and Benefits

This medication is primarily used for the symptomatic management of chronic stable angina and the long-term support of certain patients with chronic heart failure. This medication is commonly used to help manage symptoms and support patient stability in the indicated conditions.

The medication is used in clinical settings that involve stable symptom patterns, such as stable angina pectoris and certain types of chronic heart failure. The therapy is utilized where symptomatic support is indicated for physical discomfort, such as chest tightness, shortness of breath, and a persistently fast heart rate. The therapy may assist with maintaining functional stability and contributes to day-to-day comfort for patients during long-term management.

This therapy is relevant for easing symptoms that interfere with daily functioning and supports the patient during symptomatic episodes by easing distress.


Quick Fact: Relief for Heightened Heart Symptoms

The medication is commonly used to help with symptoms related to heightened physiological activity, such as palpitations, by easing distress and assisting with maintaining functional stability when these symptoms are more noticeable.

Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Эквакард — Official Regulatory Information

This section outlines the official eligibility and non-eligibility criteria for Эквакард (Amlodipine/Lisinopril Fixed-Dose Combination), strictly based on governmental regulatory documentation.


Eligibility Scope

Category Regulatory Status
Populations Allowed Adult patients with essential hypertension.
Populations Contraindicated Patients with known hypersensitivity to Amlodipine, Lisinopril, or any ACE inhibitor; history of angioedema related to ACE inhibitor use; hereditary or idiopathic angioedema; pregnancy; or cardiogenic shock.
Age-Related Rules Use is not established and not recommended in pediatric patients (children and adolescents). Caution is advised for older adults.
Organ Function Restrictions Caution is required for use in patients with severe renal impairment or hepatic impairment.
Pregnancy/Lactation Status Contraindicated in pregnancy and not recommended for women who are breastfeeding/lactating.
Other Restrictions Caution is required in patients with severe congestive heart failure or those who are volume-depleted.

Connection to the Overall Eligibility Profile

Regulatory documents define who can and cannot use the medicine by establishing definitive exclusions based on prior clinical history (angioedema), known hypersensitivity, and physiological status (pregnancy). Use is additionally limited to populations where safety and efficacy are established (adults) and constrained by a patient's organ function, requiring regulatory caution for those with impaired hepatic or renal function.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines interactions for the dual components (Amlodipine and Lisinopril) as documented in official government regulatory information.

Interaction Scope
Medicinal Product Categories ARBs, Neprilysin Inhibitors, CYP3A Inhibitors, NSAIDs, mTOR Inhibitors, Potassium-Sparing Diuretics, Lithium.
Specific Interacting Medicines Simvastatin, Aliskiren, Clarithromycin, Itraconazole.
Mechanistic Basis in Label Pharmacokinetic interaction via CYP3A inhibition (Amlodipine); Pharmacodynamic interaction via Dual Inhibition of the Renin-Angiotensin System (RAAS) (Lisinopril).
Interaction-Related Restrictions Simvastatin dose must not exceed 20 mg daily [FDA/MHRA]. Aliskiren is contraindicated in diabetic patients [FDA].
Timing-Based Rules A mandatory 36-hour wash-out period is required when switching to or from a Neprilysin Inhibitor (e.g., Sacubitril/Valsartan) [FDA].
Population-Specific Notes Elderly patients may exhibit higher blood levels of Lisinopril due to reduced renal clearance [FDA].

Official Interaction Statements

  • Contraindicated Combination: Co-administration with Neprilysin Inhibitors is prohibited due to the risk of angioedema. A 36-hour separation time is required.
  • Dose Limitation: The Amlodipine component increases the exposure of Simvastatin, necessitating the 20 mg maximum daily dose restriction for Simvastatin.
  • Exposure Increase: Co-administration with strong CYP3A Inhibitors (e.g., Itraconazole) may result in an increase in Amlodipine systemic exposure.
  • Hyperkalemia Risk: Co-administration with Potassium Supplements or Potassium-Sparing Diuretics may lead to an additive increase in serum potassium.
  • Toxicity Risk: Co-administration with Lisinopril may increase serum concentrations of Lithium, raising the risk of toxicity.

Regulatory documents define the product's interaction structure by outlining mandatory contraindications, specific dose limits, and necessary wash-out periods related to its two active components.

Advertisements

Mechanism of Action

How Эквакард Works: Mechanism of Action

Modulating Ion Channel Activity

Эквакард acts within mechanistic domains associated with receptor-mediated signaling by binding to and blocking L-type voltage-dependent calcium channels located on the membranes of vascular smooth muscle cells and cardiac tissue. This targeted interaction limits the influx of extracellular calcium ions into these cells, initiating the core pharmacodynamic cascade.


Vascular Relaxation and Hemodynamics

The restricted calcium entry modifies early molecular steps essential for muscle contraction by suppressing signaling sequences. This pathway action alters processes driven by distinct cellular excitation patterns, resulting in the sustained relaxation of arterial vascular smooth muscle. This physiological consequence reduces peripheral vascular resistance, thereby modulating the overall hemodynamic state.


Influence on Myocardial Tension

By influencing systems characterized by heightened vasoconstrictive signaling, the mechanism engages in pathways that regulate biological processes within the cardiovascular system. The combined effect of vascular smooth muscle relaxation and, for some calcium channel blockers, influence on cardiac conduction, results in a decrease in myocardial wall tension.

Advertisements

Dosage and Administration Information

Official Administration Guidelines

Эквакард (Amlodipine/Lisinopril Fixed-Dose Combination) is an oral medication with a standardized administration protocol.


Administration Scope Instruction
Route of Administration The medicine is strictly for oral administration as a film-coated tablet.
Dosing Schedule The typical initial and maintenance dosage is one tablet per day. Dosage is generally a substitution for equivalent, individually-titrated maintenance doses of the separate components.
Timing in Relation to Meals The tablet may be taken with or without food, as its absorption is not clinically altered by food.
Preparation Requirements The tablet must be swallowed whole with an adequate amount of fluid. If the tablet is scored, the score line is only to facilitate ease of swallowing and is not to be used to divide the tablet into half-strength doses.
Age-Group Rules Older Adults: Dosage increases should be made with care, often starting at the lower dose range of the Amlodipine component (e.g., 2.5 mg).
Missed-Dose Rules If a dose is missed, it should be skipped if it is close to the time of the next scheduled dose; a double dose must not be taken to compensate for the missed dose.
Special Procedural Conditions The FDC is generally not recommended for use in patients with moderate to severe renal impairment (creatinine clearance leq 30 mL/min) due to the necessary individualized dose adjustments of the Lisinopril component. Use in patients with hepatic impairment requires careful titration, starting at the lowest possible dose.

Instruction Classifications

Classification Detail
Administration Method Type Oral
Frequency Pattern Daily (once daily)
Basis of Use Clinical Guidelines
Use-Context Constraints Intended for use as substitution therapy after components have been successfully titrated.

Resulting Procedural Structure

The protocol involves a concise, long-term approach:

  • Take one tablet orally, once daily.
  • Swallow the tablet whole with fluid.
  • Maintain a consistent schedule by taking the tablet at the same time each day.
  • If a dose adjustment is deemed necessary, a period of 7 to 14 days is generally required to pass before the new dose is assessed.

This instruction set defines the long-term, once-daily oral regimen for this combination medicine, emphasizing dose consistency and the importance of using the prescribed combination strength as a whole unit without further division.

Advertisements

Recent Clinical Evidence

Эквакард: Recent Clinical Evidence

Mechanism of Action Studies

Research examined the drug's intended pathway of action. This involves blocking a specific enzyme related to the inflammatory process. These foundational studies focused on the intended drug target in laboratory and preclinical models.


Clinical Efficacy Trials (Phase III)

Primary Efficacy

Studies examined whether symptoms were affected in participants with moderate to severe illness. The primary endpoints of the key registration trials were defined by standardized clinical scoring systems. Research explored the relationship between the treatment and the frequency of flare-ups over a 52-week observation period.

Long-Term Outcomes

Research has reported findings related to changes in disease activity over time. The evidence gathered is from studies where participants received this treatment. Follow-up research assessed health-related quality of life measures and the need for rescue medication in participants.


Combination Therapy and Subgroups

Research examined the results reported when using the treatment in combination with existing therapy. These studies compared results of the combination regimen to the existing therapy alone, based on established clinical indicators. Studies evaluated various doses of the treatment.

Subgroup analyses have focused on participant characteristics such as age, disease duration, and prior treatment history.

  • Age and Co-morbidities: Studies included elderly participants and those with co-morbidities.
  • Organ Function: The evidence base includes information about treatment response in participants with varying degrees of kidney function and liver function.

Studies observed changes in acute symptoms following the initiation of the treatment. The study reported the magnitude of the effect observed using statistical measures (e.g., odds ratios and hazard ratios).

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Эквакард (FAQ)


Q: Is Эквакард used for high blood pressure or other heart problems?

Regulatory documents indicate that the medication is primarily indicated for the treatment of high blood pressure (hypertension). Its active components are also individually approved in regulatory documents to address other cardiovascular concerns. The Amlodipine component is individually recognized in regulatory documents for its use in treating chronic stable angina.


Q: How long after starting Эквакард will I notice any changes?

While the blood pressure-lowering effect begins soon after the first dose, the full effect of the medication requires a period of consistent use. Official information indicates that the full and optimal blood pressure reduction may take between two and four weeks of continuous daily use to be fully reached and maintained.


Q: Do side effects from Эквакард usually go away after a few weeks?

Some common adverse reactions may lessen over the course of treatment, according to observations from clinical studies. However, the component Lisinopril is associated with a common adverse effect, which is a persistent, dry cough. Regulatory information notes that this type of cough may continue or take a prolonged period, potentially up to a month, to resolve even after stopping the medication.


Q: Is there an interaction between Эквакард and alcohol consumption?

According to official product labeling, alcohol can interact with the Amlodipine component by having an additive effect in lowering blood pressure. This additive effect may increase the possibility of symptoms associated with lowered blood pressure, such as dizziness.


Q: What happens if I forget to take a dose of Эквакард?

Official administration guidelines provide clear instructions regarding a missed dose. If a dose is forgotten, it should be skipped entirely if it is close to the time the next scheduled dose is due. Regulatory instructions strictly state that a double dose should not be taken to compensate for the missed one.


Q: What scientific evidence supports the effectiveness of Эквакард?

Clinical studies required for regulatory approval confirmed that the combined product is an effective treatment strategy. Registration trials confirmed that the use of this medication resulted in statistically significant reductions in both systolic and diastolic blood pressure compared to control groups.


Q: How does Эквакард affect my heart rate?

Regulatory studies indicate that the Lisinopril component typically produces a smooth blood pressure reduction with no clinically significant change in heart rate. The Amlodipine component also works to influence cardiac conduction, which affects the heart muscle and tension, contributing to the overall effect.


Q: Is Эквакард a blood thinner?

Official documentation does not classify this medication as a blood thinner. It is officially defined as an Antihypertensive Agent (a Calcium Channel Blocker and an ACE Inhibitor) to control blood pressure. Blood thinners belong to a separate drug class used for managing blood clots.


Q: Does Эквакард need to be taken at a specific time of day?

Official administration guidelines instruct the user to take the tablet once daily and to maintain a consistent schedule. This means taking it at the same time each day to ensure steady drug levels, but official documents do not specify whether the morning or evening is required.


Q: Does Эквакард treat heart failure?

The combined product is indicated in regulatory documents primarily for the treatment of hypertension. However, the Lisinopril component is individually approved in regulatory documents for the treatment of heart failure as an adjunctive therapy.


Q: Is there a risk of weight gain when using Эквакард?

Official labeling for the Amlodipine component lists weight gain as an uncommon adverse reaction. Additionally, the Amlodipine component is frequently associated with edema (swelling or fluid retention), particularly of the ankles.


Q: Are there any common foods or supplements that interact with Эквакард?

The absorption of the Lisinopril component is specifically stated in regulatory information as not being affected by food. However, official warnings note that consuming Grapefruit Juice may increase the drug exposure of the Amlodipine component.


Q: Can Эквакард be used by people who also have diabetes?

Research indicates that the combination of these drug classes is widely studied for use in patients with hypertension and diabetes. The Lisinopril component is recognized in guidelines for its potential use in managing blood pressure for those with diabetes.


Q: What is the average length of time people stay on Эквакард?

Treatment for chronic conditions like hypertension is considered long-term therapy by regulatory agencies. In many cases, the approach for chronic conditions like hypertension involves continuous, long-term use.


Q: Does Эквакард make my blood pressure drop too low?

Official safety information lists Symptomatic Hypotension as a potential serious adverse reaction. This describes a severe drop in blood pressure that may cause symptoms. Regulatory documents indicate that this adverse reaction is a concern, particularly when therapy is initiated.


Q: Why is Эквакард sometimes taken with other cardiovascular medicines?

Regulatory documents approve the medication for use alone or in combination with other antihypertensive agents. This combination approach is used to achieve better blood pressure control when a patient's hypertension is not adequately managed by single-drug therapy.


Q: Is Эквакард a diuretic (water pill)?

No. The medication is officially classified as an Antihypertensive Agent. Its components are a Calcium Channel Blocker (Amlodipine) and an ACE Inhibitor (Lisinopril), neither of which are classified as diuretics (water pills).


Q: What is the risk of an allergic reaction to Эквакард?

The medication should not be used if there is a history of hypersensitivity to its active components or any ACE inhibitor. Furthermore, the serious adverse reaction of Angioedema (severe swelling of the face or throat) is a documented, potentially fatal allergic-type reaction linked to the ACE inhibitor component.


Q: Can I take vitamins or herbal supplements while on Эквакард?

Official product information notes that the use of certain Multivitamins with Minerals may reduce the effects of the Amlodipine component. Patients are generally advised in official documents to disclose the use of all other medications, vitamins, and supplements to their healthcare team.


Q: What is the difference between how Эквакард works and how a statin works?

The medication works by combining the effects of a calcium channel blocker and an ACE inhibitor to reduce blood pressure. A statin, by contrast, is a separate class of drug that works primarily by reducing the production of cholesterol in the liver to manage fat levels in the blood.


Q: Is it true that I only need Эквакард if I feel bad?

According to official information, this medication is used to manage the chronic condition of hypertension. Because high blood pressure often does not cause symptoms, official documentation establishes that continuous, long-term use is typically required for managing the condition.


Q: What is the half-life of Эквакард?

The half-life refers to the time it takes for half of the drug to be eliminated from the body. The Lisinopril component has an effective half-life of accumulation of approximately 12.6 hours. The Amlodipine component has a longer terminal elimination half-life of about 30–50 hours, which supports the drug's once-daily dosing regimen.


Q: Is there a maximum time I can safely take Эквакард?

Official product labeling for the components indicates that for chronic conditions like hypertension, treatment is considered long-term therapy. For the management of hypertension, continuous, long-term treatment may be required.


Q: Does Эквакард have any impact on sexual function?

Official labeling reports that the Amlodipine component has been associated with impotence or erectile dysfunction as a less common adverse reaction. The Lisinopril component is not commonly linked to this side effect.


Q: Does Эквакард affect sleep patterns?

Official reports of adverse reactions for the Amlodipine component list somnolence (drowsiness) as a possibility. Additionally, the persistent dry cough caused by the Lisinopril component is sometimes reported to interfere with sleep.

Advertisements

How should Эквакард be stored and disposed of?

How to Store and Dispose of Эквакард?

All storage and disposal procedures for Эквакард (Amlodipine/Lisinopril) are strictly defined by official regulatory documentation to ensure product stability and safety.

Storage Conditions and Protection

The tablets must be kept at controlled room temperature, typically 20 C to 25 C, and must be protected from excess moisture and light. It is required to store the medicine in its original container, ensuring it remains tightly closed and is not kept in high-humidity areas, such as a bathroom. The product must not be frozen and must be kept away from excess heat.

Disposal and Child Safety

For public safety, it is a mandatory requirement to store the medication out of the reach and sight of children. Expired or unused tablets should be disposed of using an official drug take-back program or by following the regulatory procedure for household trash disposal (mixing the tablets with an undesirable substance in a sealed bag). The medicine must not be flushed down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Эквакард found in:

A-Z Index: